The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Avapritinib for Advanced Systemic Mastocytosis

Selective KIT D816V inhibitor transforming aggressive disease outcomes

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Avapritinib for Advanced Systemic Mastocytosis?

Advanced systemic mastocytosis encompasses aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

Most cases are driven by KIT D816V mutation, which activates mast cell proliferation and survival.

Avapritinib is a potent and selective inhibitor of KIT D816V approved by FDA in 2021 for advanced systemic mastocytosis.

The PATHFINDER and EXPLORER trials demonstrated overall response rates above 70 percent including molecular responses.

Replaces midostaurin as the preferred KIT-targeted agent in advanced disease.

Symptoms

Mediator-related symptoms: flushing, anaphylaxis, abdominal pain, diarrhea.
Organ damage: hepatosplenomegaly, cytopenias, malabsorption, weight loss.
Bone disease: osteoporosis, pathological fractures, skeletal pain.
Skin: urticaria pigmentosa, mastocytomas, persistent itching.
Constitutional symptoms: fatigue, fevers, drenching night sweats.

Risk Factors

KIT D816V mutation positivity (greater than 90 percent of advanced disease).
B and C findings on bone marrow biopsy indicate organ damage requiring therapy.
Elevated serum tryptase correlates with disease burden.
High mast cell burden (greater than 30 percent of bone marrow cells in MCL).
Advanced age and frailty influence treatment intensity choices.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Recurrent anaphylaxis or worsening mediator symptoms.
  • New cytopenias, weight loss, or unexplained organ enlargement.
  • Pathological fractures or progressive bone pain.
  • Cognitive changes during treatment requiring evaluation for cerebral edema.
  • Persistent gastrointestinal symptoms with malabsorption.

Treatment Methods

01
Avapritinib 200 mg orally once daily as starting dose for advanced systemic mastocytosis.
02
Dose modifications for cytopenias, especially thrombocytopenia (more frequent than imatinib class).
03
Cognitive effects (memory, mood) require dose reduction or interruption.
04
Monitor with serum tryptase, KIT D816V allele burden, complete blood counts every 4 weeks initially.
05
Cytoreductive therapy combinations (cladribine) considered for mast cell leukemia.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.